MiSight 1 day
Demand Driver
MiSight drove CooperVision sphere/other category growth; regulatory approvals in FDA, NMPA and MHLW jurisdictions support myopia management expansion
Relevance 88·Dependency 55·Confidence 95
Source evidence
“Sphere, other grew primarily through MiSight and MyDay, offset by a decrease in legacy hydrogel products.”
silicone hydrogel lens components
Supplier Dependency
Sole-source suppliers for silicone hydrogel lens components create supply disruption risk; mitigated by contracts and safety stocks but alternative supplier switching on short notice could disrupt product supply.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“if current raw material suppliers fail to supply sufficient materials on a timely basis, or at all for any reason, we could experience inventory shortages and disruption in the supply of products”
contact lens wearers
Demand Driver
Growth tied to lower wearer dropout rates via improved designs/materials and shift toward single-use and monthly modalities
Relevance 80·Dependency 70·Confidence 90
Source evidence
“We believe that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and materials and the growth of preferred modalities such as single-use and monthly wearing options.”
Global and regional key account customers
Customer Exposure
Customer consolidation means key accounts represent a larger share of revenue; disruption to these relationships would materially harm the business.
Relevance 80·Dependency 65·Confidence 90
Source evidence
“global and regional key account customers now represent a larger proportion or concentration of our business and any disruption to these relationships may have a material adverse impact on our business.”
hospitals, surgery centers, OB/GYN offices, fertility clinics
Revenue Exposure
CooperSurgical revenue depends on hospitals, surgery centers, OB/GYN offices and fertility clinics, whose purchasing depends on payor coverage and reimbursement.
Relevance 80·Dependency 65·Confidence 90
Source evidence
“Market acceptance and sales of our CooperSurgical products to our customers, who primarily consist of hospitals and surgery centers, OB/GYN medical offices and fertility clinics, will depend on the availability of payor coverage”
Silicone hydrogel
Raw Material Dependency
Silicone hydrogel contact lens manufacturing requires continued process improvements to remain cost-effective and competitive.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“materials such as silicone hydrogel require improvements to our manufacturing processes to make them cost-effective.”
International operations / currency fluctuations
Currency Exposure
Approximately half of net sales are generated outside the US, exposing results to currency exchange rate fluctuations.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“fluctuations in currency exchange rates adversely affecting our results;”
Inflation
Revenue Exposure
Inflation raises manufacturing costs and may not be offset by price increases; macro weakness can reduce customer purchases.
Relevance 75·Dependency 60·Confidence 85
Source evidence
“Our global business has been negatively affected by local economic conditions, including inflation, increasing labor costs, recession, and currency exchange rate fluctuations”
EU MDR/IVDR
Regulatory Exposure
New or changed medical device regulations including EU MDR/IVDR affect Cooper's operations in the contact lens and medical device industries; cited as a significant risk.
Relevance 75·Dependency 60·Confidence 90
Source evidence
“including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR).”
Paragard IUD
Revenue Exposure
Paragard contraceptive IUD sales were a primary driver of CooperSurgical office and surgical revenue growth in FY2025
Relevance 75·Dependency 40·Confidence 93
Source evidence
“office and surgical net sales increased primarily due to increased sales of Paragard contraceptive intrauterine devices”
tariffs
Geopolitical Exposure
Company explicitly cites escalating global trade barriers and tariffs as risks that have adversely affected and could further affect sales, cash flow and performance
Relevance 72·Dependency 40·Confidence 90
Source evidence
“escalating global trade barriers and disruptions, such as the impact of tariffs. These risks and uncertainties have adversely affected our sales, cash flow and performance in the past”
Tariffs and trade sanctions
Geopolitical Exposure
New or retaliatory tariffs and sanctions may disrupt supply chain, customer relationships and competitiveness.
Relevance 70·Dependency 55·Confidence 85
Source evidence
“Changes in import and export policies, including new, increased or retaliatory tariffs, sanctions and countersanctions and customs restrictions by the U.S. and foreign governments, may disrupt our supply chain”
tariffs and trade barriers
Cost Driver
Tariffs, customs duties and retaliatory trade measures raise costs and could disrupt supply of product to or through affected countries; mitigation efforts themselves carry impact.
Relevance 70·Dependency 50·Confidence 85
Source evidence
“as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures.”
US healthcare reform (IRA, OBBBA)
Regulatory Exposure
IRA Medicare price negotiations and OBBBA Medicaid/ACA changes exert downward pricing pressure and may reduce patient access and demand for Cooper products.
Relevance 70·Dependency 50·Confidence 85
Source evidence
“These changes may affect patient access to care and alter the reimbursement environment for providers and manufacturers.”
Foreign exchange movements materially affect reported sales and earnings; FX added ~$16.0M to CooperVision sales and caused an $8.0M intercompany FX loss
Relevance 70·Dependency 45·Confidence 90
Source evidence
“the growth experienced across all categories was positively impacted by favorable foreign exchange rate fluctuations of approximately $16.0 million.”
EMEA was CooperVision's fastest-growing region at $1,064.4M (+8%), helped by favorable FX; combined with Americas it represents the majority of contact lens revenue
Relevance 68·Dependency 39·Confidence 95
Source evidence
“The growth in EMEA was positively impacted by favorable foreign exchange rate fluctuations.”
Online / direct-to-consumer distribution models
Competitive Exposure
Internet-driven fulfillment and telemedicine models may interfere with CooperVision's customer relationships and strategy.
Relevance 65·Dependency 50·Confidence 85
Source evidence
“CooperVision's failure to adapt to the threats posed by these new and emerging distribution models and Internet driven services may have a material adverse impact on our business.”
third-party payor coverage and reimbursement
Revenue Exposure
Reimbursement levels may be reduced or eliminated and coverage denied based on clinical guidelines or cost-effectiveness assessments, with even perceived changes causing demand volatility.
Relevance 65·Dependency 50·Confidence 85
Source evidence
“Reimbursement levels may be reduced or eliminated altogether, and coverage may be denied or restricted based on clinical guidelines, cost-effectiveness assessments, or changes in regulatory classification.”
large consolidating customers
Customer Exposure
M&A-driven consolidation of large customers globally increases revenue concentration and customer bargaining power.
Relevance 60·Dependency 55·Confidence 85
Source evidence
“Market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers.”
Interest expense / financing costs
Cost Driver
The Company carries material debt service costs, with interest expense of $100.0M in FY2025, down from $114.3M in FY2024.
Relevance 55·Dependency 50·Confidence 90
Source evidence
“Interest expense100.0 114.3 105.3”
Corneal refractive surgery (Lasik)
Technology Dependency
Lasik and new pharmaceuticals could substitute for contact lenses and reduce demand for optical products.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“corneal refractive surgical procedures such as Lasik surgery and the development of new pharmaceutical products may decrease the demand for our optical products.”
EU Corporate Sustainability Reporting Directive (CSRD)
Regulatory Exposure
Evolving ESG disclosure regimes (CSRD, California climate rules, SEC climate rule) impose compliance cost and litigation risk.
Relevance 50·Dependency 40·Confidence 80
Source evidence
“the European Union Corporate Sustainability Reporting Directive (CSRD) became effective in 2023 and applies to both EU and non-EU entities.”